A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Inhibition of tumor growth factor-β (TGF-β) receptor type I potentiated the activity of sorafenib in preclinical models of hepatocellular carcinoma (HCC). Galunisertib is a small-molecule selective inhibitor of TGF-β1 receptor type I, which demonstrated activity in a phase 2 trial as second-line HCC...

Descripción completa

Detalles Bibliográficos
Autores principales: Kelley, R.K., Gane, E., Assenat, E., Siebler, J., Galle, P.R., Merle, P., Hourmand, I.O., Cleverly, A., Zhao, Y., Gueorguieva, I., Lahn, M., Faivre, S., Benhadji, K.A., Giannelli, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708671/
https://www.ncbi.nlm.nih.gov/pubmed/31295152
http://dx.doi.org/10.14309/ctg.0000000000000056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708671/
https://www.ncbi.nlm.nih.gov/pubmed/31295152
http://dx.doi.org/10.14309/ctg.0000000000000056

Ejemplares similares